ES2563632T3 - Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa - Google Patents

Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa Download PDF

Info

Publication number
ES2563632T3
ES2563632T3 ES09380191.8T ES09380191T ES2563632T3 ES 2563632 T3 ES2563632 T3 ES 2563632T3 ES 09380191 T ES09380191 T ES 09380191T ES 2563632 T3 ES2563632 T3 ES 2563632T3
Authority
ES
Spain
Prior art keywords
controlled release
alginic acid
composition
intravenously
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09380191.8T
Other languages
English (en)
Inventor
Salvador Grancha Gamon
Anna Nardi Ricart
Josep Maria Suñe Negre
Josep Ramón Tico Grau
Monserrat Miñarro Carmona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40793335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2563632(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols SA filed Critical Grifols SA
Application granted granted Critical
Publication of ES2563632T3 publication Critical patent/ES2563632T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Composición biocompatible para administración intravenosa para la liberación controlada de un ingrediente activo, comprendiendo un factor coagulante de la sangre, en el que el ingrediente activo está incluido en micropartículas de ácido algínico o sales del mismo, en la que estas micropartículas tienen dimensiones menores o iguales 5 a 5 μm y un potencial Z negativo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES09380191.8T 2008-12-23 2009-12-17 Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa Active ES2563632T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200803671A ES2319158B1 (es) 2008-12-23 2008-12-23 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
ES200803671 2008-12-23

Publications (1)

Publication Number Publication Date
ES2563632T3 true ES2563632T3 (es) 2016-03-15

Family

ID=40793335

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200803671A Expired - Fee Related ES2319158B1 (es) 2008-12-23 2008-12-23 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
ES09380191.8T Active ES2563632T3 (es) 2008-12-23 2009-12-17 Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200803671A Expired - Fee Related ES2319158B1 (es) 2008-12-23 2008-12-23 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.

Country Status (17)

Country Link
US (1) US7931916B2 (es)
EP (1) EP2201940B1 (es)
JP (2) JP5297994B2 (es)
CN (1) CN101757631B (es)
AR (1) AR074820A1 (es)
AU (1) AU2009248454B2 (es)
BR (1) BRPI0906284A2 (es)
CA (1) CA2688047C (es)
CL (1) CL2009002204A1 (es)
ES (2) ES2319158B1 (es)
HK (1) HK1141451A1 (es)
HU (1) HUE028485T2 (es)
MX (1) MX2009014178A (es)
NZ (1) NZ582166A (es)
PL (1) PL2201940T3 (es)
RU (1) RU2476235C2 (es)
UY (1) UY32354A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102429862B (zh) * 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液
RU2519158C1 (ru) * 2013-03-28 2014-06-10 Федеральное государственное бюджетное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения Российской Федерации (ФГБУ "СарНИИТО" Минздрава России) Биодеградируемое раневое покрытие и способ получения биодеградируемого раневого покрытия
CN104888226A (zh) * 2014-03-06 2015-09-09 中国科学院大连化学物理研究所 一种蛋白质和/或多肽类物质的制剂
CA2987209A1 (en) * 2015-06-10 2016-12-15 Evonik Rohm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
US11464748B2 (en) 2016-02-01 2022-10-11 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
WO2018144556A1 (en) * 2017-01-31 2018-08-09 Georgia Tech Research Corporation Compositions and methods for inhibiting shear-induced platelet accumulation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518046A (en) 1982-06-21 1985-05-21 Deere & Company Multiple implement hitch and transport
WO1991009119A1 (en) * 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
RU2071765C1 (ru) * 1994-07-14 1997-01-20 Российский научно-исследовательский институт гематологии и трансфузиологии Способ получения липосом
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
JP3765338B2 (ja) * 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
JPH11130698A (ja) 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
EP1498100A4 (en) * 2002-03-29 2008-04-02 Shiseido Co Ltd COMPOSITE POWDER AND THIS INCLUDING COSMETICS
CA2484965A1 (en) * 2002-04-30 2003-11-13 Canadian Blood Services Encapsulated cells to elicit immune response
WO2006028996A2 (en) 2004-09-03 2006-03-16 Trustees Of Tufts College Emulsan-alginate microspheres and methods of use thereof
US20060260777A1 (en) * 2005-04-27 2006-11-23 Julia Rashba-Step Surface-modified microparticles and methods of forming and using the same
AU2006302744B8 (en) 2005-10-21 2011-02-10 Living Cell Products Pty Limited Encapsulation system
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
EP2012751A4 (en) * 2006-03-21 2010-11-24 Morehouse School Of Medicine NEW NANOPARTICLES FOR THE DELIVERY OF ACTIVE AGENTS
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
EP2061509A2 (en) 2006-08-14 2009-05-27 Wayne State University Polymer-surfactant nanoparticles for sustained release of compounds
EP1958622A1 (en) * 2006-11-07 2008-08-20 Royal College of Surgeons in Ireland Method of producing microcapsules
US9114127B2 (en) 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis
DE202008009270U1 (de) 2008-07-10 2009-11-12 Steelcase Werndl Ag Wandförmiges Standmöbel
EP2159523B1 (en) 2008-08-29 2018-08-01 Electrolux Home Products Corporation N.V. Refrigeration equipment and console system for use therein

Also Published As

Publication number Publication date
CN101757631A (zh) 2010-06-30
CN101757631B (zh) 2013-02-27
AU2009248454B2 (en) 2011-07-28
RU2476235C2 (ru) 2013-02-27
EP2201940B1 (en) 2016-02-24
EP2201940A1 (en) 2010-06-30
AR074820A1 (es) 2011-02-16
UY32354A (es) 2010-07-30
US20100159017A1 (en) 2010-06-24
CA2688047A1 (en) 2010-06-23
NZ582166A (en) 2011-06-30
PL2201940T3 (pl) 2016-06-30
CL2009002204A1 (es) 2010-05-07
HK1141451A1 (en) 2010-11-12
ES2319158A1 (es) 2009-05-04
JP2013136636A (ja) 2013-07-11
US7931916B2 (en) 2011-04-26
MX2009014178A (es) 2010-06-30
HUE028485T2 (en) 2016-12-28
JP5297994B2 (ja) 2013-09-25
RU2009147838A (ru) 2011-06-27
JP2010150257A (ja) 2010-07-08
BRPI0906284A2 (pt) 2013-07-30
JP5698296B2 (ja) 2015-04-08
ES2319158B1 (es) 2010-01-26
CA2688047C (en) 2012-08-21
AU2009248454A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
ES2563632T3 (es) Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
CL2019003432A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
GT201400285A (es) Formulacion de anticuerpos
BR112015022433A2 (pt) dispositivos de liberação de droga com componente permeável à droga e métodos
AR091089A1 (es) Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
EA201491685A1 (ru) Препарат для инъекций
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
BR112013017750A8 (pt) nanocápsulas com revestimento polimérico
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ECSP099439A (es) Composición de liberación sostenida y métodos para producirla
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ES2614481T3 (es) Composición para la administración de principios activos mediante dispositivos de implante
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
AR061802A1 (es) Composicion que tiene una actividad que previene la germinacion, procedimientos para obtener dichas composiciones y uso de las mismas
ES2598753T3 (es) Composición farmacéutica para el tratamiento de la tendinitis calcificada y/o bursitis calcificada